Publication:
A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.

Loading...
Thumbnail Image

Date

2020-01-02

Authors

Oberweis, Caroline Veronique
Marchal, Juan Antonio
Lopez-Ruiz, Elena
Galvez-Martin, Patricia

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Mary Ann Liebert, Inc. Publishers
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Over the past decades, a wide range of tissue-based products (TBPs) have emerged as new therapeutic alternatives to conventional approaches, giving an opportunity to treat pathologies that have not been cured yet. TBPs are constituted by living/nonliving and genetically/nongenetically modified cells or tissues, which might be combined with materials that support their structure, molecules that favor the cellular environment, and even medical devices to create functional substitutes. These medicinal products are used for the repair, replacement, restoration, or regeneration of a damaged tissue in the patient. The clinical translation of these innovative products has led to the establishment of new and comprehensive regulatory schemes by regulatory bodies. The knowledge and adaptation to these regulatory shifts is essential for the pharmaceutical industries and academia, as it promotes the development of TBPs and their approval and marketing. TBPs follow different regulatory approaches depending on the jurisdiction in which the product is intended to be marked. The European Union and United States of America have developed a clear and specific regulatory pathway for TBPs. However, in other jurisdictions, the oversight of these products remains still challenging. This review describes and updates the main legal considerations, which must be implemented throughout the marketing authorization application process of a TBP, defining the regulatory framework of the main health agencies and outlining the major differences between them. Impact statement Tissue-based products (TBPs) are complex to regulate since many jurisdictions do not have an adapted legislation for these. Thus, researches may not consider crucial regulatory aspects during the development of these products, leading to failure for their marketing approval by regulatory bodies. This review describes how a TBP is overseen under several key jurisdictions and offers an overview of the steps that sponsors should follow until the product launch onto the market. Thus, this study provides guidance for nonexperts in regulatory affairs, boosting the understanding of the regulations governing these products, fasting, and easing the development of the same.

Description

MeSH Terms

Cell- and Tissue-Based Therapy
Decision Making
Global Health
Humans
Legislation, Medical
Marketing
Product Surveillance, Postmarketing
Risk Assessment

DeCS Terms

Humanos
Salud global
Toma de decisiones
Tratamiento basado en trasplante de células y tejidos
Vigilancia de productos comercializados
Legislación médica
Medición de riesgo
Mercadotecnía

CIE Terms

Keywords

advanced therapies, marketing authorization, medical devices, regulatory frameworks, tissue engineering, tissue-based products

Citation

Oberweis CV, Marchal JA, López-Ruiz E, Gálvez-Martín P. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products. Tissue Eng Part B Rev. 2020 Apr;26(2):181-196.